Efficacy and Failure Patterns Following Target Volume and Dose Reduction After Neoadjuvant Therapy in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Head & Neck · 2025
DOI: 10.1002/hed.28037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Xiong Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
In this study, we aimed to analyze the efficacy and failure patterns of contouring target volume based on the residual tumor and decreasing the dose to the area of tumor regression after neoadjuvant therapy in locoregionally advanced head and neck squamous cell carcinoma (HNSCC).
Methods
We retrospectively analyzed the patients with locoregionally advanced HNSCC treated by our group from May 2011 to June 2023. All patients received neoadjuvant therapy followed by intensity‐modulated radiation therapy. Gross tumor volumes for the primary tumor and metastatic lymph nodes were delineated according to postneoadjuvant extension. The tumor shrinkage after neoadjuvant therapy was included in the high‐risk clinical target volume (CTV1) and prescribed a dose of 60 Gy. Kaplan–Meier analysis was employed to calculate local recurrence‐free survival (LRFS), regional recurrence‐free survival (RRFS), overall survival (OS), and distant metastasis‐free survival (DMFS). Failure patterns were analyzed by mapping the location and extent of locoregional recurrence onto pretreatment planning CT.
Results
This study included a total of 114 patients, with a median follow‐up of 34 months. The 5‐year LRFS, RRFS, OS, and DMFS rates were 70.2%, 70.7%, 74.8%, and 73.8%, respectively. Among the 14 patients with recurrences, there were 5 local failures, 6 regional recurrences, and 3 both local and regional recurrences. All local recurrences occurred within the 95% isodose line, classified as in‐field failures. Only one regional recurrence was marginal failure. No out‐of‐field failure was observed.
Conclusion
Reduction of target volume after neoadjuvant therapy and distribution of 60 Gy of dose to the tumor regression area may be feasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
- Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
ORCID-Profile: Zheng Wu, Zichen Qiu, Yong Su
Zitieren
APA
Zhou, X., Wu, Z., Qiu, Z., Lin, M., Tao, Y., & Su, Y. (2025). Efficacy and Failure Patterns Following Target Volume and Dose Reduction After Neoadjuvant Therapy in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Head & Neck. https://doi.org/10.1002/hed.28037
Vancouver
Zhou X, Wu Z, Qiu Z, Lin M, Tao Y, Su Y. Efficacy and Failure Patterns Following Target Volume and Dose Reduction After Neoadjuvant Therapy in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Head & Neck. 2025. doi:10.1002/hed.28037
BibTeX
@article{Zhou2025,
author = {Zhou, Xiong and Wu, Zheng and Qiu, Zichen and Lin, Minchuan and Tao, Yalan and Su, Yong},
title = {Efficacy and Failure Patterns Following Target Volume and Dose Reduction After Neoadjuvant Therapy in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.28037}
}
EUVIMED